Dabigatran's `Real-World' Data About Risk of Myocardial Infarction and Gastrointestinal Bleeding Contradicts With Randomized Trials

Simple item page
dc.contributor.authorSipahi, Ilke
dc.contributor.authorCelik, Seden
dc.contributor.authorAkyol, Ahmet
dc.date.accessioned2023-02-21T12:33:35Z
dc.date.available2023-02-21T12:33:35Z
dc.date.issued2013-01-01
dc.description.issue10
dc.description.issueSEP 3
dc.description.pages945-946
dc.description.volume62
dc.identifier.doi10.1016/j.jacc.2013.05.066
dc.identifier.urihttps://hdl.handle.net/11443/1529
dc.identifier.urihttp://dx.doi.org/10.1016/j.jacc.2013.05.066
dc.identifier.wosWOS:000323900300020
dc.publisherELSEVIER SCIENCE INC
dc.relation.ispartofJOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
dc.titleDabigatran's `Real-World' Data About Risk of Myocardial Infarction and Gastrointestinal Bleeding Contradicts With Randomized Trials
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Dabigatran's 'Real-World' Data About Risk of Myocardial Infarction and Gastrointestinal Bleeding.pdf
Size:
150.91 KB
Format:
Adobe Portable Document Format
Download

Collections

WOS